Euglena Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
1,042
- Stock Symbol
-
2931
- Investments
-
24
- Share Price
-
$1.96
- (As of Friday Closing)
Euglena General Information
Description
euglena Co Ltd is a biotechnology company that researches, develops, produces, and markets microalgae. The company focuses on commercializing its algae research for a variety of uses, including functional foods and cosmetics. Euglena also researches ways to use its microalgae for carbon capture and biofuel production. The company operates in three segments: Healthcare Business, Biofuel Business, and Other Businesses.
Contact Information
Website
www.euglena.jpCorporate Office
- G-Base Tamachi 2nd Floor
- 5-29-11 Shiba, Minato-ku
- Tokyo, 108-0014
- Japan
Corporate Office
- G-Base Tamachi 2nd Floor
- 5-29-11 Shiba, Minato-ku
- Tokyo, 108-0014
- Japan
Euglena Timeline
Euglena Stock Performance
As of 13-Nov-2026, Euglena’s stock price is $1.96. Its current market cap is $274M with 140M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.96 | $1.96 | $1.92 - $2.97 | $274M | 140M | 661K |
Euglena Financials Summary
As of 30-Sep-2026, Euglena has a trailing 12-month revenue of $338M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 331,128 | 382,060 | 400,650 | 649,065 |
| Revenue | 338,339 | 336,546 | 314,417 | 330,809 |
| EBITDA | 37,583 | 24,853 | 9,501 | |
| Net Income | (1,061) | (5,379) | (4,292) | (18,874) |
| Total Assets | 431,665 | 462,401 | 466,509 | 422,740 |
| Total Debt | 137,260 | 176,952 | 165,045 | 177,771 |
Euglena Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Euglena Comparisons
Industry
Financing
Details
Euglena Competitors (1)
One of Euglena’s competitors is Amoeba, a Formerly VC-backed company based in Chassieu, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Amoeba | Formerly VC-backed | Chassieu, France |
Euglena Patents
Euglena Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2026146738-A | Composition | Pending | 04-Mar-2025 | ||
| JP-2026129051-A | Cosmetics | Pending | 30-Jan-2025 | ||
| JP-2026092444-A | Fuel oil containing 50% to 90% by volume of hydrogenated vegetable oil | Pending | 26-Nov-2024 | ||
| JP-2026080528-A | Device for detecting target substance and use thereof | Pending | 31-Oct-2024 | ||
| JP-2026032430-A | Method for selecting microorganism for high sugar yield | Pending | 13-Aug-2024 |
Euglena Signals
Euglena Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Euglena Investments & Acquisitions (24)
Euglena’s most recent deal was a Merger/Acquisition with Jeffer (Beverages). The deal was made on 05-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Jeffer (Beverages) | 05-Jan-2026 | Merger/Acquisition | Beverages | ||
| Joint Venture (Petronas / Eni / Euglena) | 26-Jul-2024 | Joint Venture | Energy Exploration | ||
| Satis Pharmaceutical | 10-Jan-2024 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Aqua Theon | 21-Nov-2023 | Early Stage VC | Food Products | ||
| Hako (Media and Information Services (B2B)) | 01-Jul-2022 | Merger/Acquisition | Media and Information Services (B2B) |
Euglena ESG
Risk Overview
Risk Rating
Updated November, 08, 2026
35.21 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Household Products
Industry
of 104
Rank
Percentile
Personal Products
Subindustry
of 84
Rank
Percentile
Euglena Exits (2)
Euglena’s most recent exit was on 15-May-2018 from Medcare. The exit was categorized as with 8 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Medcare | 15-May-2018 | Completed |
|
||
| Amelieff | 31-Jan-2016 | Corporate | Completed |
Euglena Affiliates
Subsidiaries (10)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| CQ Ventures | Fukuoka, Japan | 2016 | |
| Hako (Media and Information Services (B2B)) | Tokyo, Japan | 2015 | |
| Genequest | Tokyo, Japan | 2013 | |
| Mej | Tokyo, Japan | 2008 | |
| Satis Pharmaceutical | Yoshikawa, Japan | 1999 |
Euglena FAQs
-
When was Euglena founded?
Euglena was founded in 2005.
-
Where is Euglena headquartered?
Euglena is headquartered in Tokyo, Japan.
-
What is the size of Euglena?
Euglena has 1,042 total employees.
-
What industry is Euglena in?
Euglena’s primary industry is Biotechnology.
-
Is Euglena a private or public company?
Euglena is a Public company.
-
What is Euglena’s stock symbol?
The ticker symbol for Euglena is 2931.
-
What is the current stock price of Euglena?
As of 13-Nov-2026 the stock price of Euglena is $1.96.
-
What is the current market cap of Euglena?
The current market capitalization of Euglena is $274M.
-
What is Euglena’s current revenue?
The trailing twelve month revenue for Euglena is $338M.
-
Who are Euglena’s competitors?
Amoeba is a competitor of Euglena.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process